Consistent with these findings, genetic inhibition of IFN-alpha signaling protects mice from SLE [22], and the anti-IFN-α monoclonal antibody anifrolumab has been recently approved by the FDA for treating SLE patients [23,24,25]. Here, IFNA1 is linked to systemic lupus erythematosus.